TrioxBio develops and commercializes proprietary synthetic small molecules to treat pathologic states caused by the overproduction of nitric oxide. The company's API, S-ethylisothiouronium diethylphosphate, MTR-104, is a nitric oxide synthase (NOS) inhibitor that blocks the production of nitric oxide, preventing the dilation of blood vessels and other detrimental effects caused by excessive NOS activity.
TrioxBio's leading candidate, MTR-107 (indicated for the prevention of recurrent intradialytic hypotension), received orphan drug designation from the FDA in August 2016. In addition, its development program received fast-track designation from the FDA in May 2018.
The company has applied to the FDA for two orphan drug designations for vasoplegic syndrome and intradialytic hypotension, and the request has been approved for intradialytic hypotension.
As part of SK Pharma Group, TrioxBio is involved in the R&D of treatments in the areas of oncology, antiviral diseases, and new drug-delivery systems.